Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(3):297–302. doi: 10.1054/bjoc.2000.1610

Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer

S L Turner 1, S Gruenewald 2, N Spry 3, V Gebski 4; on behalf of the Metastron Users Group
PMCID: PMC2363737  PMID: 11161391

Abstract

93 patients with hormone refractory metastatic prostate cancer were entered on a prospective study to measure reduction in pain and changes in quality of life (QoL) after the administration of 150 MegaBequerel (MBq) Strontium-89 (Sr-89). QoL was assessed using a validated instrument, the Functional Living Index – Cancer (FLIC) questionnaire. Pain response was measured using the Radiation Therapy Oncology Group scoring system. Overall there was limited QoL improvement over 3 months following Sr-89. However, in the 53 patients (63%) achieving pain responses, QoL did significantly improve within 6 weeks of receiving Sr-89 compared to patients with stable or worsening bone pain, and this was independent of other parameters that might influence QoL outcomes, such as performance status, baseline PSA and extent of skeletal disease (P = 0.004). PSA ‘response’ occurred in 30 patients (37%) over 4 months after Sr-89. This did not appear to correlate with clinical improvement. This study supports the presumption that improvement in pain following Sr-89 is accompanied by better QoL. The lack of correlation of PSA response and clinical parameters indicates that in the palliative setting, PSA may not provide a useful surrogate for treatment outcome. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: quality of life, strontium-89, bone pain, prostate cancer

Full Text

The Full Text of this article is available as a PDF (145.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Laing A. H., Ackery D. M., Bayly R. J., Buchanan R. B., Lewington V. J., McEwan A. J., Macleod P. M., Zivanovic M. A. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991 Sep;64(765):816–822. doi: 10.1259/0007-1285-64-765-816. [DOI] [PubMed] [Google Scholar]
  2. Lewington V. J., McEwan A. J., Ackery D. M., Bayly R. J., Keeling D. H., Macleod P. M., Porter A. T., Zivanovic M. A. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954–958. doi: 10.1016/0277-5379(91)90257-e. [DOI] [PubMed] [Google Scholar]
  3. Malmberg I., Persson U., Ask A., Tennvall J., Abrahamsson P. A. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Urology. 1997 Nov;50(5):747–753. doi: 10.1016/S0090-4295(97)00326-9. [DOI] [PubMed] [Google Scholar]
  4. McEwan A. J., Amyotte G. A., McGowan D. G., MacGillivray J. A., Porter A. T. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun. 1994 Jul;15(7):499–504. doi: 10.1097/00006231-199407000-00002. [DOI] [PubMed] [Google Scholar]
  5. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  6. Porter A. T., McEwan A. J., Powe J. E., Reid R., McGowan D. G., Lukka H., Sathyanarayana J. R., Yakemchuk V. N., Thomas G. M., Erlich L. E. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):805–813. doi: 10.1016/0360-3016(93)90309-j. [DOI] [PubMed] [Google Scholar]
  7. Porter A. T., McEwan A. J. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993 Jun;20(3 Suppl 2):38–43. [PubMed] [Google Scholar]
  8. Quilty P. M., Kirk D., Bolger J. J., Dearnaley D. P., Lewington V. J., Mason M. D., Reed N. S., Russell J. M., Yardley J. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994 Apr;31(1):33–40. doi: 10.1016/0167-8140(94)90411-1. [DOI] [PubMed] [Google Scholar]
  9. Robinson R. G., Blake G. M., Preston D. F., McEwan A. J., Spicer J. A., Martin N. L., Wegst A. V., Ackery D. M. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989 Mar;9(2):271–281. doi: 10.1148/radiographics.9.2.2467331. [DOI] [PubMed] [Google Scholar]
  10. Schipper H., Clinch J., McMurray A., Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984 May;2(5):472–483. doi: 10.1200/JCO.1984.2.5.472. [DOI] [PubMed] [Google Scholar]
  11. Tong D., Gillick L., Hendrickson F. R. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982 Sep 1;50(5):893–899. doi: 10.1002/1097-0142(19820901)50:5<893::aid-cncr2820500515>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES